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Abstract
Background: Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease associated with chronic
arthritis. Early diagnosis and effective therapy of SJIA is desirable, so that complications are avoided. The PRO-KIND
initiative of the German Society for Pediatric Rheumatology (GKJR) aims to define consensus-based strategies to
harmonize diagnostic and therapeutic approaches in Germany.
Methods: We analyzed data on patients diagnosed with SJIA from 3 national registries in Germany. Subsequently, via
online surveys and teleconferences among pediatric rheumatologists with a special expertise in the treatment of SJIA,
we identified current diagnostic and treatment approaches in Germany. Those were harmonized via the formulation of
statements and, supported by findings from a literature search. Finally, an in-person consensus conference using
nominal group technique was held to further modify and consent the statements.
Results: Up to 50% of patients diagnosed with SJIA in Germany do not fulfill the International League of Associations
for Rheumatology (ILAR) classification criteria, mostly due to the absence of chronic arthritis. Our findings suggest that
chronic arthritis is not obligatory for the diagnosis and treatment of SJIA, allowing a diagnosis of probable SJIA. Malignant,
infectious and hereditary autoinflammatory diseases should be considered before rendering a diagnosis of probable SJIA.
There is substantial variability in the initial treatment of SJIA. Based on registry data, most patients initially receive systemic
glucocorticoids, however, increasingly substituted or accompanied by biological agents, i.e. interleukin (IL)-1 and IL-6
blockade (up to 27.2% of patients). We identified preferred initial therapies for probable and definitive SJIA, including
step-up patterns and treatment targets for the short-term (resolution of fever, decrease in C-reactive protein by 50%
within 7 days), the mid-term (improvement in physician global and active joint count by at least 50% or a JADAS-10
score of maximally 5.4 within 4 weeks) and the long-term (glucocorticoid-free clinically inactive disease within 6 to
12 months), and an explicit treat-to-target strategy.
Conclusions: We developed consensus-based strategies regarding the diagnosis and treatment of probable or
definitive SJIA in Germany.
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Background
Systemic juvenile idiopathic arthritis (SJIA) is a rare and
serious autoinflammatory disorder characterized by
systemic inflammation (hectic quotidian fevers, typical
rash, serositis, hepatosplenomegaly, lymphadenopathy,
acute-phase reaction) and variably accompanied or
followed by chronic arthritis [1–3].
The hypothesis exists that early effective treatment of
SJIA during a “window of opportunity” may fundamen-
tally affect its long-term outcome and, specifically,
reduce the risk of a chronic articular course [4–6].
Hence, early diagnosis and treatment of SJIA may be es-
sential in order to avoid long-term complications. How-
ever, guidance on establishing an early diagnosis of SJIA
is limited. The existing International League of Associa-
tions for Rheumatology (ILAR) classification criteria for
SJIA have been criticized [7]. Classification criteria for
the closely related and presumably identical condition of
adult-onset Still’s disease (AOSD) exist (Yamaguchi or
Fautrel criteria) but have not been formally validated in
children [8, 9]. The various classification criteria are
summarized in Additional file 1: Table S1.
Historically, SJIA has been effectively treated with gluco-
corticoids, however, at the cost of substantial adverse
effects [10, 11]. Recently advances in treatment have been
made via the introduction of biologic drugs targeting
interleukin (IL)-1 and IL-6 [12–14]. The outcomes of pa-
tients with SJIA have improved markedly due to the avail-
ability of these effective antirheumatic therapies [6, 12–
19]. Evidence-based guidelines for the treatment of SJIA
exist in Germany but are limited in their scope [20]. More
recently, treatment recommendations based on evidence
and expert opinion for patients with SJIA have been devel-
oped by the American College of Rheumatology (ACR) in
2011 and updated in 2013, covering a wide array of
clinical scenarios [15, 17]. The North American Child-
hood Arthritis & Rheumatology Research Association
(CARRA) has developed consensus treatment plans based
on the usual clinical practice of providers within their
group [16]. By experience, treatment of SJIA is highly vari-
able among different practitioners and may often be de-
layed and/or inadequate; data from inception cohorts and
registries indicate that inactive disease is often reached late,
for example, beyond the first year of treatment [21, 22].
While there are cross-sectional data on the treatment and
outcomes of SJIA in Germany, these data do not allow a
precise analysis of treatment steps taken by pediatric rheu-
matologists in this country [21]. Furthermore, while treat-
to-target and tight-control have been central principles in
the care of adult patients with rheumatoid arthritis [23],
these principles have not been integrated into available
recommendations for the treatment of JIA. However, some
authors have suggested developing treat-to-target strategies
for pediatric rheumatology as well [24, 25].
The PRO-KIND (PROjekte zur Klassifikation, Überwa-
chung und Therapie in der KINDerrheumatologie;
projects for the classification, monitoring and therapy in
pediatric rheumatology) initiative is a sub-committee of
the German Society for Pediatric Rheumatology (GKJR)
and aims to define consensus-based strategies to
harmonize diagnostic and treatment approaches in
Germany. This initiative was started since it was per-
ceived that children with juvenile rheumatic diseases in
Germany are currently often treated too late or not with
the most up-to-date therapeutic options. Overall, the
long-term goal of this project is to improve the quality
of care and outcome for patients with SJIA. To meet this
challenge, the goals of the PRO-KIND initiative are to
foster the use of harmonized standardized diagnostic
and therapeutic strategies with defined targets.
Methods
PRO-KIND SJIA project group and expert panel
The SJIA project group was initiated in October 2015.
Altogether, 11 experienced pediatric rheumatologists
participated in several online surveys and five telephone
conferences. They collected and analyzed the literature,
planned the process and drafted different statements.
This included the following key steps: 1) Planning and
consensus on aims of the project group, 2) retrieval of
real-life patient data from 2 registries in Germany (see
study populations below), 3) retrieval of evidence from
literature on the following topics: Diagnostic/classifica-
tion criteria or case definitions, diagnostics or differen-
tial diagnosis, therapeutic targets, monitoring, and
medications, 4) a survey of diagnostic approaches based
on clinical case scenario (in addition to members of the
core project group, another 21 pediatric rheumatologists
with particular experience with SJIA participated, to-
gether forming the expert panel), 5) survey analysis by
the project group, and formulation of statements based
on the aforementioned steps, and 6) discussion and
consensus of all statements in a revised form during a
face-to-face consensus conference organized in June
2016. Members of the project group were experienced in
the management of patients with SJIA and had managed
up to 150 patients with SJIA in the last 5 years (median:
15 patients); 6 out of 11 members of the expert panel
had previously pursued research in SJIA. The expert
panel was formed by additionally recruiting pediatric
rheumatologists from the 13 top referring centers to the
Autoinflammatory Disease registry (AID-Net) and all
centers participating in the inception cohort of newly
diagnosed patients with JIA (ICON-JIA).
Study populations
Data was retrieved from 2 registries and 1 inception co-
hort regarding the current practice of diagnosing and
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treating SJIA in Germany. For this study, all patients
who entered the registries with a diagnosis of SJIA were
analyzed whether ILAR classification criteria were
fulfilled or not.
(1)The national pediatric rheumatology database
(Kerndokumentation) is a central registry
maintained by the German Rheumatism Research
Center in Berlin since 1997, with the goal to
monitor most patients with pediatric rheumatic
diseases longitudinally. Clinical data, including
current and past antirheumatic therapies, physician
global disease activity, joint examination findings,
and pertinent laboratory findings are entered
annually. Overall 61 pediatric rheumatology centers
or providers participate in this database (30 children
hospitals, 20 university hospitals and 11 pediatric
rheumatologists in private practice). Data from 2007
until 2013 were available for analysis.
(2)ICON-JIA in Germany is a controlled observational
cohort study to observe patients with a recent
diagnosis of JIA, i.e. within 12 months before
enrollment, for at least 10 years, including 11 large
German pediatric rheumatology centers. ICON
started in 2010 and is collecting various data, every
3 months during the first year and every 6 months
thereafter. In addition to 975 patients with JIA, 489
children without JIA were included in the cohort.
(3)AID-Net since 2009 is monitoring patients of 42
German pediatric rheumatology centers with various
autoinflammatory diseases including SJIA and
collects detailed clinical and laboratory data during
routine and acute visits.
Parameters retrieved
The following parameters regarding the diagnosis of SJIA
were retrieved for this study from ICON-JIA and the
AID-Net: prevalence of arthritis, fever, rash, lymphaden-
opathy, hepatosplenomegaly, serositis, pharyngitis,
leukocyte count, C-reactive protein (CRP) level, erythro-
cyte sedimentation rate (ESR) and S100 protein levels. Re-
garding treatment of SJIA, medications used in the first
year of therapy were retrieved from the 3 databases, spe-
cifically nonsteroidal anti-inflammatory drugs (NSAIDs),
systemic glucocorticoids, intraarticular glucocorticoids,
methotrexate, anakinra, canakinumab, tocilizumab, adali-
mumab, etanercept, and cyclosporin A. Furthermore,
where available, information on the disease course (mono-
cyclic, polycyclic, chronic) and the attainment of clinically
inactive disease was retrieved [26].
Online survey of current clinical practice
In addition, to better understand current concepts in
clinical practice, an online survey depicting 6 different
clinical scenarios was developed. It had the goal to
reflect a spectrum of clinical findings that may be seen
in patients with suspected, probable or definitive SJIA
(Additional file 2: Table S2). These clinical scenarios
contained information about pertinent history of present
illness, family history, travel history, pattern of fever,
pattern of rash, physical examination findings (including
the presence or absence of arthritis, arthralgia, myalgia,
lymphadenopathy, hepatosplenomegaly, serositis) and
essential laboratory data (including complete blood
count, CRP, sedimentation rate, ferritin, transaminases,
LDH, albumin, fibrinogen, triglycerides, prothrombin
time, partial thromboplastin time, D-dimers) as well as
physician and patient global scores, Questions were then
targeted to determine the various diagnostic approaches,
terminology used and treatments rendered. The survey
was sent out to the 33 members of the expert panel.
Statistical analysis
Descriptive statistics were used to report the registry
data. The various classification criteria and case defin-
ition were applied to the AID-Net and ICON datasets.
Since there were missing data, the proportion of patients
fulfilling the criteria was also calculated by means of
extrapolation, defining for each individual criterion that
its prevalence over the entire SJIA population is
reflected by the prevalence among those patients for
whom the criterion was tested. For the extrapolation, it
was assumed that the individual criteria were independ-
ent from each other.
Consensus process
Diagnostic and treatment patterns were retrieved from the
registry and inception cohort data, online survey and
evidence for selected clinical questions was extracted from
the literature. Based on these data, statements were devel-
oped and judged via an online survey among the 11
experts from the project group; each statement could be
accepted without further comment, conditionally accepted
(comment provided) or rejected. Following this online
survey, the statements were refined and presented at an
in-person consensus conference in Münster, Germany, on
June 24, 2016. Twenty experts were present during this
consensus conference, and the process was guided by a
professional moderator and assisted by 3 scientists who
were not pediatric rheumatologists and one patient repre-
sentative/parent. We used nominal group technique for
consensus building. For each individual statement, the
following procedures were performed: the statement and
its background were presented by an individual expert
member who had extracted the statement in question.
Subsequently, every participant of the consensus confer-
ence had 1 min of time available to raise issues with the
statement being discussed. These issues were recorded on
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a flip-chart. Then there was a vote via an electronic voting
system (audience response system) to identify the top 3
items needing further discussion, followed by a 15-min
open discussion of these items to further improve the
statement. Subsequently a final round of anonymous
voting took place during which each participant could ei-
ther accept or reject the respective statement. Consensus
was considered to be present if at least 80% of experts
supportive a statement. The overall consensus process is
outlined in Additional file 3: Figure S1.
Level and strength of evidence and grades of
recommendation
We used the Oxford Centre for Evidence-based Medicine
levels of evidence and grades of recommendation to further
support the individual evidence for the developed state-
ments [27]. Levels of evidence range from 1 to 5, and
grades of recommendation from A to D.
Results
Characteristics of patients diagnosed with SJIA in
Germany
Only 59.9 and 57.1% patients diagnosed with SJIA in the
AID registry and the ICON-JIA cohort, respectively, had
arthritis at any time during the follow-up. In both the
AID registry and the ICON-JIA cohort, exact data
regarding the length and pattern of fever and the dur-
ation of arthritis at time of diagnosis were not available.
For the purpose of this analysis, it was assumed that, if
fever was documented to be present, the fever pattern
was typical, and, if any arthritis was documented, that it
met the requirement for ILAR classification. Table 1
demonstrates the patient characteristics in detail. For the
AID registry, detailed data regarding age at disease
onset, duration of disease and presence or absence of
arthritis were available.
Diagnosis of SJIA and testing in different clinical
scenarios
An online survey among experts in the diagnosis and
treatment of SJIA was circulated among the expert
panel. Twenty-eight of 33 addressees replied (85% return
rate). The initial question was whether the scenario was
representative of SJIA or not, followed by the question
regarding the nomenclature in a case like this. Of note,
many experts requested additional diagnostic testing,
since only 38 to 58% of experts designated a diagnosis of
definitive SJIA based on the initially presented data
(Additional file 4: Table S3). The following diagnostic
tests were considered to be potentially useful (at least
50% consent), in addition to the parameters that had
already been presented as part of the case scenario (data
given as mean ± standard deviation across all case
scenarios): echocardiography 97,8 ± 3,4%, blood cultures
96.8 ± 2.4%, ultrasound of the abdomen 90.4 ± 9.4%,
serum S100 proteins 91.4 ± 2.9%, chest X-ray 85.4 ±
3.6%, serum immunoglobulins 79.9 ± 3.7%, ECG 75.1 ±
8.2%, urine studies 75.7 ± 3.3%, autoantibodies 70.5 ±
Table 1 Clinical parameters of patients diagnosed with SJIA within the German AID registry and ICON-JIA
German AID registry (n = 207) ICON-JIA (n = 35)
Parameter Number of patients in
whom parameter is
available
Number of patients in
whom the parameter
is positive (%)
Number of patients in
whom parameter is
available
Number of patients in whom
the parameter is positive (%)
Fever 207 202 (97.6%) 35 35 (100%)
Arthritis 207 124 (59.9%) 35 20 (57.1%)
Arthralgia (but not arthritis) 207 76 (36.7%) 35 2 (5.7%)
Rash 207 149 (72.0%) 35 30 (85.7%)
Serositis 207 38 (18.4%) 35 6 (17.1%)
Lymphadenopathy 207 44 (21.3%) 35 12 (34.3%)
Hepato- and/or splenomegaly 207 48 (23.2%) 35 16 (45.7%)
Pharyngitis 207 7 (3.4%) N/A N/A
Leukocytosis (WBC > 10,000/mm3) 154 129 (83.8%) 33 21 (63.6%)
Leukocytosis (WBC > 15,000/mm3) 154 92 (59.7%) 33 10 (30.3%)
CRP≥ 30 mg/l 158 125 (79.1%) 33 15 (45.5%)
ESR≥ 50 mm/h 122 90 (73.8%) 26 12 (46.2%)
Marked systemic inflammationa 115 110 (95.7%) 35 19 (54.3%)
Extremely elevated S100 proteinsb 30 23 (76.7%) 19 5 (26.3%)
AID Autoinflammatory disease, GKJR Society for Pediatric Rheumatology, ICON-JIA Inception cohort of newly diagnosed patients with juvenile idiopathic arthritis,
ILAR International League of Associations for Rheumatology, N/A Data not available, SJIA Systemic juvenile idiopathic arthritis, WBC White blood cell count
aWBC > 15,000/mm3, C-reactive protein> 30 mg/l, and/or erythrocyte sedimentation rate > 50 mm/h
bExtremely elevated S100A8/A9 (> 10,000 ng/ml) or S100A12 (> 1500 ng/ml) serum level
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5.7%, joint ultrasound 69.9 ± 3.6%, peripheral blood
smear 68.6 ± 4.4%, serum complement levels 61.9 ± 6.0%,
bone marrow aspiration 55.4 ± 9.4%, serum procalcitonin
50.3 ± 6.2%. Other tests were considered to be essential
by fewer than 50% of participant (listed in order of
descending frequency): rheumatoid factor, soluble IL-2
receptor levels, serum amyloid A, plasma cytokines,
lymphocyte subpopulations, lumbar puncture, NK cell
degranulation, pulmonary function testing, NK cell
function, whole body MRI, MRI of painful joints or
PET-CT.
Current pharmacologic treatment based on registry and
cohort data
Data on the treatment and disease course of SJIA was
retrieved from the national pediatric rheumatology data-
base, the ICON-JIA cohort and the AID-Net registry
(Table 2).
Current pharmacologic treatment based on case
scenarios
In the aforementioned online survey, in addition to diag-
nostic procedures, we also queried about treatment deci-
sions. These data are represented in Additional file 5:
Table S4. It is apparent that systemic glucocorticoids are
a preferred treatment modality for SJIA among experts
in Germany since between 58 and 91% experts would
suggest using glucocorticoids in the various scenarios.
Non-steroidal anti-inflammatory drugs were suggested
by 48 to 71% of experts, depending on the scenario, but
only as adjunctive therapy. However, biologics (anakinra,
canakinumab or tocilizumab) are also preferred fre-
quently as an initial therapy, depending on the scenario
by 29 to 50% of experts.
Development of individual statements in the consensus
conference and their evidence
Individual statements regarding the diagnosis and man-
agement of SJIA were discussed and consented during
the final consensus conference. The agreed upon
statements, the consensus level and the level of evidence
are shown in Table 3. For statement 1 (case definitions
for PRO-KIND strategies), the current SJIA and AOSD
classification criteria, and Childhood Arthritis &
Rheumatology Research Association (CARRA) case def-
inition were identified and analyzed (see Additional file
1: Table S1). For statement 2 (diagnostics and differential
diagnosis), a literature search was initiated regarding
various blood biomarkers routinely available in Germany
(see Additional file 6: Table S5). Several reports were
identified discussing the occurrence of malignancy mim-
icking SJIA, therefore supporting statement 3A [28–31].
Table 2 Treatment patterns and disease courses of new-onset SJIA in Germany
Database National pediatric rheumatology database (2011–2013) ICON-JIA (2010–2015) AID registry (2008–2015)
Number SJIA patients 125 34 251
Initial pharmacologic treatments
Timeframe assessed Patients with disease duration of
12 months or less
At time of enrollment (within
12 months of disease onset)
and within three months prior
In the first three months
of treatment
NSAIDs 55 (44.0%) 29 (85.3%) 145 (57,8%)
Systemic glucocorticoids 75 (60.0%) 33 (97.1%) 178 (70.9%)
Intraarticular glucocorticoids 6 (4.8%) 4 (11.8%) N/A
Methotrexate 68 (54.4%) 16 (47.1%) 102 (40.6%)
Anakinra 17 (13.6%) 5 (14.7%) 31 (12.4%)
Canakinumab 5 (4.0%) 2 (5.9%) 7 (2.8%)
Tocilizumab 12 (9.6%) 2 (5.9%) 12 (4.8%)
Adalimumab 1 (0.8%) 0 (0%) 0 (0%)
Etanercept 2 (1.6%) 1 (2.9%) 6 (2.4%)
Cyclosporin A 0 (0%) 1 (2.9%) 0 (0%)
Disease course N/A Inactive disease:
3 months: 56%
6 months: 64%
9 months: 70%
12 months: 70%
18 months: 68%
24 months: 80%
Sufficient data for 156 pts.:
Monocyclic 42 (26.9%)
Polycyclic 62 (39.7%)
Chronic 52 (33.3%)
Among 108 pts. with arthritis:
Monocyclic 19 (17.6%)
Polycyclic 39 (36.1%)
Chronic 50 (46.2%)
AID Autoinflammatory diseases, ICON-JIA Inception cohort of patients with new-onset juvenile idiopathic arthritis, N/A Not available, NSAIDs Non-steroidal anti-
inflammatory drugs, SJIA Systemic juvenile idiopathic arthritis
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Table 3 Consensus statements regarding the diagnosis and management of SJIA
Statements Consensus Levels of evidence
and grades of
recommendationa
Statement 1 Strategies of the PRO-KIND SJIA project group apply to the following patients with new-onset disease:
(A) Patients with systemic juvenile idiopathic arthritis according to ILAR categorization 100% 1a, A
(B) Patients with suspected SJIA who do not fulfill the ILAR criterion of arthritis 100% 4, D
Statement 2
(A) The demonstration of systemic inflammation, i.e. usually elevated C-reactive protein, erythrocyte sedimentation
rate, leukocytes and/or ferritin) is essential for diagnosing SJIA at disease onset
100% 1b, A
(B) Measurement of specific autoantibodies may be useful in order to rule out other conditions. 100% 5, D
(C) Measurement of phagocyte-specific S100 proteins may be helpful to differentiate between SJIA and other
diseases associated with fever. There is insufficient data in regards to interleukin-18 and procalcitonin for
the diagnosis of SJIA.
100% 2b-4, C
Statement 3
(A) Malignancies are important differential diagnoses for SJIA. If suspected, an extended panel of diagnostic tests,
including chest radiography, ultrasound of the abdomen and lymph nodes, bone marrow aspiration, and, if
appropriate, biopsy of lymph nodes or other involved organs should be pursued. The indication for bone
marrow aspiration should be reviewed critically prior to initiating a glucocorticoid therapy. An elevated LDH,
uric acid and cytopenias represent pertinent findings.
100% 5, D
(B) Infections are important differential diagnoses for SJIA. An adapted search for infections should be pursued
(see guideline “Fever of unknown origin”).
100% 5, D
(C) Hereditary autoinflammatory syndromes are important differential diagnoses for SJIA. Molecular genetic
testing should be pursued if clinical suspicion for a known hereditary autoinflammatory syndrome exists.
91.7%b 5, D
(D) There are no data from controlled studies regarding the utility of imaging studies in the diagnosis of SJIA.
However, sonography and MRI are important modalities to assess joint and organ manifestations, to
differentiate from other conditions and to monitor disease activity.
100% 5, D
(E) Generally, in case of insufficient response to antirheumatic therapies, especially glucocorticoids, interleukin-1
or interleukin-6 blockade, the diagnosis of SJIA has to be critically reconsidered.
100% 5, D
Statement 4
(A) The overall treatment target is achieving a clinically inactive disease, ideally without glucocorticoids, and,
eventually, clinical remission. Clinically inactive disease is aimed for within six to twelve months.
100% 2A
(B) The following interim targets are aimed for:
a. Resolution of fever within one week of the start of treatment
b. Improvement of CRP by at least 50% within one week of the start of treatment
c. Marked improvement of overall disease activity within four weeks of the start of treatment, i.e. improvement
of the physician global disease activity by at least 50%, reduction of actively inflamed joints (if present) by at
least 50% and/or a JADAS10-Score of maximally 5.4
100% 2A
Statement 5
(A) NSAIDs and DMARDS: Optionally, NSAIDs may be used for treating SJIA even though no data from
randomized placebo-controlled clinical trials are available. The only approved DMARD for treating SJIA
is methotrexate.
92% 4B
(B) Biologics: Positive data from clinical trials are available for IL-1 blockade (anakinra and canakinumab), IL-6
blockade (tocilizumab) and, in a limited fashion, TNF-alpha blockade (etanercept).
90% 1A
(C) Glucocorticoids: High-dose systemic glucocorticoids are an effective and proven treatment for SJIA. 100% 1A
(D) Intraarticular glucocorticoids may be used for treating arthritis in patients with SJIA. 91% 4C
Statement 6
(A) Initial treatment: In patients with probable SJIA, high-dose systemic glucocorticoids may be used, either as i.v.
pulse therapy and/or as daily glucocorticoids with subsequent dose reduction. Alternatively, anakinra may be
used, even as a monotherapy without glucocorticoids. The use of canakinumab or tocilizumab is currently
discussed.
100% 2A
(B) In case of inadequate response (interim targets not reached), i.v. pulse glucocorticoid therapy may be
repeated, or an increased dose of anakinra may be considered. In case of initial exclusive glucocorticoid
therapy, IL-1 blockade or IL-6 blockade may be introduced. In case of initial anakinra monotherapy, additional
treatment with glucocorticoids or changing to another biologic may be considered.
100% 1A/2A
(C) In case of persistent or recurrent signs of systemic disease activity, biologics (IL-1 blockade or IL-6 blockade)
may be introduced (especially in case of previous exclusive glucocorticoid therapy or a glucocorticoid-
100% 1A/2A
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Multiple infections may mimic some or most of the
clinical manifestations of SJIA. Since the probability for
various infections strongly depends on clinical circum-
stances, exposures and risk factors, the working group
concluded that testing for specific infections was not
warranted under all circumstances and that, rather, a
reasonable clinical approach regarding testing for infec-
tions should be used as outlined in the German guide-
line in respect to fever of unknown origin [32]. There
was insufficient data to represent the utility of various
imaging studies in the diagnosis of SJIA and statement
3C is based on expert opinion. Since most patients with
SJIA demonstrate an excellent response to glucocortic-
oid, anti-IL-1 or anti-IL-6 therapy, the lack of such a
response should prompt reconsideration of the diagnosis
of SJIA (statement 3D) [12–14, 33]. Statement 4 defines
the treatment targets. Essentially, the treatment targets
should be reached in succession, indicating that the pri-
ority in SJIA therapy is control of systemic inflammation
followed by overall well-being and control of arthritis. If
a treatment goal is not reached, changes in treatment
are required. For this purpose, the initial treatment tar-
get focuses on the absence of fever and marked reduc-
tion in CRP (by at least 50%) and the interim target
includes the physician global assessment and the count
of joints with active arthritis and/or the juvenile arthritis
disease activity score (JADAS)-10 which has been vali-
dated for different categories of JIA, including SJIA [34].
Statement 5 addresses the available treatment options
for patients with SJIA, indicating strong evidence for the
efficacy of using glucocorticoids, IL-1 and IL-6 blockade.
Statement 6 addresses the treatment of patients with
probable SJIA, including a preference for treatment with
high-dose glucocorticoids and/or IL-1 blockade. State-
ment 7 tackles the treatment of patients with definitive
SJIA, also addressing specific issues, such as the use of
methotrexate and alternative biologics, including tumor
necrosis factor (TNF) blockers and abatacept. Table 5
summarizes our case definitions for patients with prob-
able and definitive SJIA. Of note, our case definition for
definitive SJIA is similar to the CARRA case definition,
i.e. the presence of any arthritis for any length of time
would satisfy the entry criteria. The ILAR criteria, for-
mally requiring 6 weeks of arthritis are felt to be unreal-
istic in the real world since most patients require
treatment much earlier.
Application of various classification criteria
The different classification criteria, i.e. the ILAR and
Yamaguchi criteria and the GKJR case definitions were
applied to the individual patient data in the AID registry
and the ICON-JIA cohort (Additional file 7: Table S6).
The probability of patients within each registry to fulfill
the various criteria and case definition was calculated,
indicating that the sensitivity of the ILAR classification
was rather poor in the AID registry and the ICON-JIA
cohort, identifying only 47.8 and 54.3% when applying the
criteria de facto, respectively (Additional file 7: Table S6).
Table 3 Consensus statements regarding the diagnosis and management of SJIA (Continued)
Statements Consensus Levels of evidence
and grades of
recommendationa
dependent disease course). If biologics were already introduced, a dose increase or a change of the biologic
can be considered.
(D) If arthritis should develop in patients with probably SJIA, the respective treatment strategy for patients with
definitive SJIA is used.
100% 4B
Statement 7
(A) In the case of SJIA with arthritis, high-dose systemic glucocorticoids may be used, either as i.v. pulse therapy
and/or as daily glucocorticoids with subsequent dose reduction. Optionally, NSAIDs, methotrexate and
intraarticular glucocorticoids may be employed.
100% 2A
(B) Alternatively, IL-1 or IL-6 blockade may be applied, possibly in combination with glucocorticoids and/or
methotrexate.
100% 1A
(C) In case of insufficient treatment response (see treatment targets), i.v. glucocorticoid pulse therapy may be
repeated, or IL-1 or IL-6 blocking agents may be increased in dose (if feasible). In case of initial glucocorticoid
therapy, IL-1 or IL- blockade may be initiated. In case of initial biological monotherapy, glucocorticoids may be
added (systemically or locally), the biological agent may be changed, or methotrexate may be added.
100% 1A
(D) In case of a predominant polyarticular arthritis and in case of lack of treatment response despite the utilization
of the approved biological agents, second-line agents, e.g. TNF blockers (etanercept or adalimumab) or
abatacept may be applied. In addition, the use of methotrexate is reasonable and intraarticular glucocorticoids
may be applied.
100% 2B
(E) If MAS should develop in the context of SJIA, the corresponding treatment strategies are used. 100% 4C
CRP C-reactive protein, DMARD Disease-modifying antirheumatic drug, IL Interleukin, ILAR International league of associations for rheumatology, MAS Macrophage
activation syndrome, NSAIDs Non-steroidal anti-inflammatory drugs, SJIA Systemic juvenile idiopathic arthritis
aaccording to the Oxford Centre for Evidence-based Medicine
bconsensus was determined in a post-consensus meeting survey among 22 experts
Hinze et al. Pediatric Rheumatology  (2018) 16:7 Page 7 of 14
In contrast, the Yamaguchi classification criteria identified
55.1 and 77.1% of patients correctly, respectively, and the
GKJR case definition identified 62.3 and 65.7%, respect-
ively. The sensitivity improved when applying the criteria
to patients with laboratory data obtained within the first
month after diagnosis in the ICON-JIA cohort and when
accounting for missing data by extrapolation (Table 4).
Treatment strategies
Treatment strategies for patients with probable/sus-
pected or definitive SJIA were derived from the agreed
upon statements. Figure 1 visualizes the treatment tar-
gets identified. Figure 2 visualizes the treat-to-target
concept and the various ramifications during the first
year of treatment of new-onset probable SJIA. The
central treatment options for probable SJIA include
high-dose systemic glucocorticoids and/or interleukin-1
blockade (anakinra). Figure 3 indicates the options for
patients with definitive SJIA. The initial treatment
options include high-dose glucocorticoids, anakinra,
canakinumab or tocilizumab. In addition, systemic
glucocorticoids, intraarticular glucocorticoids, NSAIDs,
and/or MTX may be used complementary during the
initial treatment. During the course of the disease, for
patients who have persistent polyarthritis without sys-
temic inflammation, treatment with tumor necrosis
factor-alpha (TNF) blockade or abatacept is an option.
Methotrexate is commonly used as an adjunctive therapy
in case of polyarthritis and intraarticular glucocorticoid
injections may be used in case of persistent arthritis.
These treatment strategies represent a harmonization of
current SJIA treatment among experts in Germany which
is independent of the current approval status of the medi-
cations addressed. However, the strategies do not address
the management of patients beyond the first year of ther-
apy. Especially in case of refractory SJIA, advice by experts
in the management of SJIA should be sought.
Discussion
We developed practice- and consensus-based statements
guiding the management of new-onset SJIA. There is a
consensus in Germany that patients with probable SJIA,
i.e. patients with a clinical phenotype similar to definitive
SJIA but lacking chronic arthritis, may be treated simi-
larly to patients with definitive SJIA. Furthermore, we
developed treat-to-target strategies for the management
of both probable and definitive SJIA. We emphasize that
these strategies are based on the harmonization of
current clinical practice and may not represent the opti-
mal way to treat SJIA.
Even though SJIA is currently classified according to
the ILAR classification criteria for JIA, its pathogenesis,
clinical characteristics and response to therapy are very
different from other categories of JIA, and SJIA is tenta-
tively considered an autoinflammatory condition [1, 35].
A presumably identical clinical syndrome has been iden-
tified in adults, i.e. AOSD for which classification criteria
have also been established, e.g. the Yamaguchi criteria or
Fautrel’s criteria [8, 9, 36]. The most important differ-
ence between the pediatric and adult criteria is that
chronic arthritis is required for the ILAR classification
for SJIA, whereas this is not required for the classifica-
tion of AOSD. In reality, many affected children show
all symptoms of SJIA except for arthritis and are never-
theless diagnosed as SJIA [37]. These patients are more
resembling of a systemic autoinflammatory disease than
of a form of JIA. We support the use of the term “prob-
able SJIA” for these patients; some experts would
consider “Still’s disease” more appropriate [7]. It is im-
portant to note that important differential diagnoses for
patients with suspected SJIA exist, including infectious,
malignant or hereditary autoinflammatory diseases.
Therefore, before concluding that a patient with merely
suspected SJIA has probable SJIA, these differential diag-
noses should be considered, and, if necessary, specifically
Table 4 Consensus approach to the categorization of definitive
or probable SJIA
Definitive SJIA Probable SJIA
Inclusion criteria
Typical fever patterna +++ +++
Arthritis in at least one
joint
+++ –
Typical (evanescent
erythematous) rash
+ +
Generalized
lymphadenopathy
+ +
Hepatomegaly or
splenomegaly
+ +
Serositis + +
Marked systemic
inflammationb
– +++
Extremely elevated S100
proteins (calgranulins)
– +
Exclusion criteria
Infection X X
Malignancy X X
Hereditary
autoinflammatory
syndrome
X X
Requirements All obligatory criteria are
fulfilled and at least one
minor criterion.
All obligatory and
at least two minor
criteria are fulfilled.
+++: obligatory criterion; +: minor criterion; X: exclusion criterion
a fever of at least two weeks’ duration that is documented to be daily
(“quotidian”) for at least three days
b marked elevation of C-reactive protein, erythrocyte sedimentation rate,
leukocytes/granulocytes and/or ferritin
- not specifically addressed in the definition
SJIA Systemic juvenile idiopathic arthritis
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ruled out. Furthermore, our understanding of molecular
characteristics of the underlying disease mechanisms is
improving [38, 39]. The serum calgranulin proteins
S100A8/A9 (calprotectin) and S100A12 are rather sensi-
tive and specific for the detection of active SJIA, and
those may be incorporated into the diagnostic approach
for SJIA [40–42]. S100 protein testing is currently widely
applied in routine clinical practice in Germany. We
believe that expert opinion is essential in cases of
suspected and probable SJIA.
Our data show that in Germany around 40% of
patients receive a diagnosis of SJIA without having
chronic arthritis and these numbers exceed those pub-
lished previously; for example, in another cohort of pa-
tients diagnosed with SJIA only around 30% fulfilled the
ILAR criteria but 88% had arthritis [37]. We agree with
others that patients may be classified as having definitive
SJIA even without formally fulfilling the ILAR “entry”
criterion of having at least 6 weeks of chronic arthritis
[16]. Since the stereotypical disease course is that of a
prodromal severe inflammatory phase, variably followed
by arthritis, it is unrealistic that patients would manifest
6 weeks of arthritis prior to establishing a diagnosis [2].
Consequently, revised classification criteria for SJIA have
been suggested and are in development [7, 43]; our data
support such a new classification. Classification criteria
are of practical importance in pediatric rheumatology
since for the participation in clinical trials classification
criteria have to be fulfilled [12, 14]. Therefore, improved
classification criteria for SJIA better reflecting the entire
spectrum of patients with SJIA are essential [7, 43].
However, classification criteria should not be misused as
diagnostic criteria since a delay of diagnosis may lead to
delayed treatment and serious complications. Unfortu-
nately, the development of accurate diagnostic criteria is
deemed impossible for most rheumatic disorders and,
therefore, both the European League against Rheumatism
(EULAR) and the American College for Rheumatology
(ACR) do not endorse the development of diagnostic
criteria [44].
The Yamaguchi criteria and the GKJR case definition
may perform better than the ILAR criteria in classifying
patients with SJIA. We assume that the GKJR case defin-
ition for probable SJIA, requiring laboratory evidence of
marked systemic inflammation, may perform better in
real life than in the registry data analyzed here. This is
Fig. 1 Treatment targets for the treatment of systemic juvenile idiopathic arthritis. Treatments should be reached sequentially. The physician global
assessment is scored on a scale of 0 to 10, where 0 represents lack of any disease activity and 10 represents maximal disease activity. The juvenile
arthritis disease activity score (JADAS)-10 represents the sum of 4 individual scores, namely the physician global assessment (range 0–10), the patient
or parent global assessment (range 0–10), the active joint count (range 0–10), and the normalized erythrocyte sedimentation rate after 1 h ([observed
rate - 20]/100, i.e. values up to 20 mm/h are scored as 0 and values equal to or above 120 mm/h are scored as 10) or C-reactive protein (CRP; [observed
CRP in mg/l – 10]/100, i.e. values up to 10 mg/l are scored as 0 and values equal to or above 110 mg/l are scored as 10)
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based on the notion that the registries did not record
inflammatory markers at the time of diagnosis but rather
at the time of enrolment, often after treatment had been
initiated and inflammatory had already improved.
The optimal treatment for patients with probable SJIA
is unclear. Still, based on clinical experience and limited
data from published trials in AOSD, it is reasonable to
expect that these patients benefit from treatments simi-
lar to those for definitive SJIA [7, 33, 45]. In addition, it
is an intriguing new concept that the early initiation of
an effective therapy may be beneficial by timely rebalancing
the immune disturbance that underlies SJIA (within a
“window of opportunity”). Therefore, timely treatment may
prevent a switch towards the later arthritic phase of the dis-
ease [4, 6]. If the concept is correct, prevention of chronic
arthritis should be targeted, in addition to treating it.
Effective and proven treatment for SJIA exist and are
approved, including glucocorticoids, IL-1 and IL-6
blocking biologicals [12–14]. Some of the treatments
discussed in this manuscript relate to non-approved
treatment options, for example, anakinra, a recombinant
IL-1 receptor antagonist. Even though anakinra is not
approved for the treatment of SJIA in Germany, it is
frequently used in the initial treatment of SJIA, probably
also reflecting current international recommendations
and consensus treatment plans [15–17]. We believe that
our consensus treatment strategies integrate well with
existing international recommendations. It is apparent
that most pediatric rheumatologists in Germany and
their ways to treat new-onset SJIA are represented in the
developed treatment strategies. It is important that the
developed strategies do not represent clinical trial proto-
cols, but they rather harmonize variations in typical
clinical practice. German physicians should use the
consensus treatment plan felt appropriate to use in a
given patient and diverge from it whenever this is in the
patient’s best interest.
While the existing ACR recommendations and CARRA
consensus treatment plans imply a treat-to-target idea, we
explicitly embrace a treat-to-target and tight-control ap-
proach [16, 17]. Treat-to-target requires the formulation
of treatment targets, close monitoring of disease activity
and adjustment of treatment if targets are not reached. It
has been demonstrated in the management of RA that a
treat-to-target strategy improves outcome irrespective of
which specific treatments were used [46, 47], essentially
Fig. 2 Treat-to-target consensus treatment strategy for the initial therapy of probable systemic juvenile idiopathic arthritis (SJIA). Maximal doses for
glucocorticoids: i.v. methylprednisolone pulse therapy (20–30 mg/kg/day [max. 1000 mg/day) for 5 days or prednisolone equivalent 1–2 mg/kg/day
(max. 80 mg/day). “Biologic” refers to anakinra, canakinumab or tocilizumab. Maximal doses for biologics: anakinra 8 mg/kg/day (max. 300 mg/day),
canakinumab max. 300 mg every 4 weeks, tocilizumab (for body weight > 30 kg) 8 mg/kg (max. 800 mg) i.v. every 2 weeks and (for body weight <
30 kg) 12 mg/kg every 2 weeks. In addition, non-steroidal anti-inflammatory drugs may be used for symptom relief throughout. Combination therapy
with biologic agents is discouraged. Abbreviations: ANA, anakinra; CAN, canakinumab; CID, clinical inactive disease; GC, glucocorticoids; IVMP, intravenous
methylprednisolone pulse; PDN, prednisone/prednisolone equivalent. *not addressed by these strategies. ↓ = decrease dose or frequency (taper); ↑ =
increase dose or frequency
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indicating that strategy may be more important than indi-
vidual medications. The ACR recommendations indicate
milestones based on the treating physician’s estimation
of global disease activity and the active joint count
but do not specify milestones earlier than after
2 weeks of treatment changes and beyond 1 month
after treatment changes [17].
There is consensus among SJIA experts in Germany
that another goal of SJIA treatment is to minimize
glucocorticoid exposure and side effects, previously
frequently seen in patients with SJIA [11]. The explicit
consensus goal is to achieve glucocorticoid-free clinical
inactive disease (CID) within 6 to 12 months after initi-
ation of treatment with CID being defined according to
the Wallace criteria [26]. Some participants argued for a
shorter time frame of 3 months for this goal but there
was no consensus for this opinion. The stated goals
appear reasonable based on data from clinical trials and
outcome data from inception cohorts [21, 22, 48].
Ideally, all patients with SJIA should be offered the
opportunity to participate in disease registries allowing
the collection of outcome data so that the disease
courses and factors affecting the disease course may be
better understood.
Furthermore, the consensus treatment strategies we
developed should complement existing or future treat-
ment guidelines. Existing treatment guidelines for SJIA
are limited by the fact that they are strictly evidence-
based; clinically relevant issues, for example, the specific
steps when initiating or escalating therapy, are often not
addressed [20]. To improve the outcome in patients with
SJIA, efforts in harmonizing treatment approaches for
SJIA (and other diseases) should be complemented by
the collection of outcome data, so that in the long-term
the outcome of different treatment strategies may be
compared by means of comparative effectiveness
research to further optimize treatment strategies. This
approach is embodied by the plan-do-study-act improve-
ment cycle used in quality improvement [49].
There are important limitations to our work: These
strategies do not address patients with long-standing
refractory disease but only patients with new-onset
disease. The patient data available from registries were
partially incomplete. The data is limited by the fact that
temporal resolution is poor for some of the databases.
For example, for the national pediatric rheumatology
database, data are obtained annually, for ICON-JIA at
most quarterly and for the AID-Net irregularly (usually
Fig. 3 Treat-to-target consensus treatment strategy for definitive SJIA. Maximal doses for glucocorticoids: i.v. methylprednisolone pulse therapy
(20–30 mg/kg/day [max. 1000 mg/day) for 5 days or prednisolone equivalent 1–2 mg/kg/day (max. 80 mg/day). “Biologic” refers to anakinra,
canakinumab or tocilizumab. Maximal doses for biologics: anakinra 8 mg/kg/day (max. 300 mg/days), canakinumab 8 mg/kg (max. 600 mg) every
4 weeks, tocilizumab (for body weight > 30 kg) 8 mg/kg (max. 800 mg) i.v. every 2 weeks and (for body weight < 30 kg) 12 mg/kg every 2 weeks.
In addition, non-steroidal anti-inflammatory drugs may be used for symptom relief throughout. Abbreviations: ANA, anakinra; CAN, canakinumab;
CID, clinical inactive disease; GC, glucocorticoids; i.a., intraarticular; IVMP, intravenous methylprednisolone pulse; MTX, methotrexate; NSAID, nonsteroidal
anti-inflammatory drug; PDN, prednisone/prednisolone equivalent; TCZ, tocilizumab; TNF, tumor necrosis factor-alpha. ↓ = decrease dose or frequency
(taper); ↑ = increase dose or frequency
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quarterly). For that reason, not all important changes in
the clinical parameters and treatment are reflected in
the collected data. Therefore, the precise sequence of
treatments rendered cannot be deduced from the data
available. The available laboratory data in the AID-Net
and ICON in most cases do not represent those that
occurred during the peak inflammatory phase of the
disease onset but rather at the time of enrollment which,
in the case of the ICON-JIA cohort, may have been up to
12 months after initial diagnosis. The statements are
consensus-based and rarely evidence-based. The outcome
of patients with probable SJIA, i.e. an autoinflammatory
illness without arthritis, is less well known, especially since
they were not included in the landmark clinical trials of
SJIA [12–14]. Some of the laboratory parameters
discussed are not globally available yet, such as the S100
proteins. The different parameters used in the statistical
model of meeting the various classifications are not inde-
pendent. Furthermore, these consensus statements do not
specifically address the management of macrophage acti-
vation syndrome (MAS), a life-threatening complication
of SJIA. In the future, a separate consensus process in-
cluding also hematologists and immunologists is planned
to develop strategies to manage MAS.
We emphasize that our statements and deductions
regarding the diagnosis of probable or definitive SJIA are
evidence-informed and consensus-based and may not
represent the optimal way to diagnose (and treat) SJIA.
However, we believe that harmonization is important in
to compare and improve different approaches. The avail-
able registries need to be improved so that detailed and
relevant information regarding patient outcomes can be
extracted. Ideally, once outcome data become available,
the strategies can be further optimized based on ongoing
circles of quality improvement [50]. Additionally, it is
important that the approach considered here is compat-
ible with international recommendations or plans on the
diagnosis and treatment of SJIA [15–17].
Conclusions
In summary, we developed consensus-based statements
and strategies on the management of SJIA by
harmonization of existing practice patterns among ex-
perts in Germany which should aid clinicians in the
work-up of patients with suspected JIA and the manage-
ment of patients with probable and definitive SJIA.
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